Literature DB >> 11337302

Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer.

B M Fisch1, B Pickett, V Weinberg, M Roach.   

Abstract

OBJECTIVES: To evaluate the effect of the dose to the bulb of the penis on postradiation potency.
METHODS: Twenty-one patients reporting potency before three-dimensional conformal radiotherapy had the dose delivered to the bulb of the penis evaluated. This was then compared with the patient assessments of post-treatment sexual function to determine whether a dose-volume relationship exists.
RESULTS: Among the patients analyzed to date, a strong dose-volume relationship and the likelihood of remaining potent after treatment seems to exist. Patients receiving a dose of less than 40 Gy to 70% of the bulb of the penis appear to have a much greater likelihood of maintaining potency. Patients receiving 70 Gy or more to 70% of the bulb of the penis appear to be at very high risk of experiencing radiation-induced impotence (P = 0.03).
CONCLUSIONS: More studies are needed to confirm these observations. If confirmed, these data suggest that by using three-dimensional-based treatment planning and carefully designed treatment fields, the potency of men treated with radiotherapy might be substantially improved.

Entities:  

Mesh:

Year:  2001        PMID: 11337302     DOI: 10.1016/s0090-4295(01)00940-2

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  17 in total

Review 1.  Sexual function and rehabilitation after radiation therapy for prostate cancer: a review.

Authors:  David-Dan Nguyen; Alejandro Berlin; Andrew G Matthew; Nathan Perlis; Dean S Elterman
Journal:  Int J Impot Res       Date:  2021-01-06       Impact factor: 2.896

2.  Erectile dysfunction after prostate three-dimensional conformal radiation therapy. Correlation with the dose to the penile bulb.

Authors:  A Magli; M Giangreco; M Crespi; A Negri; T Ceschia; G De Giorgi; F Titone; G Parisi; S Fongione
Journal:  Strahlenther Onkol       Date:  2012-09-29       Impact factor: 3.621

3.  Penile bulb sparing in prostate cancer radiotherapy : Dose analysis of an in-house MRI system to improve contouring.

Authors:  F Böckelmann; M Hammon; S Lettmaier; R Fietkau; C Bert; F Putz
Journal:  Strahlenther Onkol       Date:  2018-10-12       Impact factor: 3.621

Review 4.  Radiation dose-volume effects and the penile bulb.

Authors:  Mack Roach; Jiho Nam; Giovanna Gagliardi; Issam El Naqa; Joseph O Deasy; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

5.  Influence of vascular comorbidities and race on erectile dysfunction after prostate cancer radiotherapy.

Authors:  Yuefeng Wang; Tian Liu; Peter J Rossi; Deborah Watkins-Bruner; Wayland Hsiao; Sherrie Cooper; Xiaofeng Yang; Ashesh B Jani
Journal:  J Sex Med       Date:  2013-06-06       Impact factor: 3.802

6.  Prospective evaluation of a specific technique of sexual function preservation in external beam radiotherapy for prostate cancer.

Authors:  Hamza Samlali; Corina Udrescu; Ariane Lapierre; Ciprian Enachescu; Alain Ruffion; Patrice Jalade; Olivier Chapet
Journal:  Br J Radiol       Date:  2017-07-27       Impact factor: 3.039

Review 7.  Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment.

Authors:  Cem Akbal; Ilker Tinay; Ferruh Simşek; Levent N Turkeri
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 8.  Permanent interstitial brachytherapy for prostate cancer: a current review.

Authors:  Jeffrey Woolsey; Nicole Miller; Dan Theodorescu
Journal:  World J Urol       Date:  2003-08-13       Impact factor: 4.226

9.  Penile Rehabilitation Strategies Among Prostate Cancer Survivors.

Authors:  Fouad Aoun; Alexandre Peltier; Roland van Velthoven
Journal:  Rev Urol       Date:  2015

10.  Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer.

Authors:  Cesare Cozzarini; Tiziana Rancati; Fabio Badenchini; Federica Palorini; Barbara Avuzzi; Claudio Degli Esposti; Giuseppe Girelli; Ilaria Improta; Vittorio Vavassori; Riccardo Valdagni; Claudio Fiorino
Journal:  Strahlenther Onkol       Date:  2016-04-14       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.